|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
None reported
|
|
gptkbp:awards
|
Various industry awards
|
|
gptkbp:ceo
|
gptkb:Dr._Y._Joseph_Chang
|
|
gptkbp:clinical_trial
|
APX005 M Phase 1/2 trial
|
|
gptkbp:employees
|
51-200
|
|
gptkbp:focus
|
Immuno-oncology
|
|
gptkbp:founded
|
gptkb:2012
|
|
gptkbp:founder
|
gptkb:Dr._Y._Joseph_Chang
|
|
gptkbp:headquarters
|
gptkb:San_Carlos,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Apexigen, Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:investment
|
Various venture capital firms
|
|
gptkbp:market
|
Global
|
|
gptkbp:mission
|
To develop innovative therapies for cancer treatment.
|
|
gptkbp:partnership
|
Various pharmaceutical companies
|
|
gptkbp:product
|
gptkb:APX005_M
|
|
gptkbp:regulatory_compliance
|
FDA approval for APX005 M
|
|
gptkbp:research_focus
|
Monoclonal antibodies
|
|
gptkbp:stock_symbol
|
APGN
|
|
gptkbp:subsidiaries
|
None reported
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.apexigen.com
|
|
gptkbp:bfsParent
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Ariad_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|